3
Announcements
Trials
Browse
Landscape
Phase
Phase 2
1
Status
Terminated
1
Sponsor Class
INDUSTRY
1
Study Type
Interventional
1
Sponsor
Cancer Type
Genitourinary
1
Conditions
Advanced Cancer
2
Urinary Bladder Neoplasms
1
Squamous Cell Carcinoma of Head and Neck
1
Non-Muscle Invasive Bladder Neoplasms
1
Melanoma
1
Lymphoid Interstitial Pneumonia
1
Laryngeal Diseases
1
Endometrial Adenocarcinoma
1
Carcinoma, Squamous Cell
1
Advanced Gastric Cancer
1
Interventions
Gemcitabine
83
Cisplatin
59
pembrolizumab
28
Paclitaxel
21
Nivolumab
21
Carboplatin
21
Cystectomy
20
Docetaxel
18
durvalumab
17
atezolizumab
17
Magnetic Resonance Spectroscopy
16
Specimen Handling
15
Radiotherapy
14
avelumab
13
Mitomycin
13
Sunitinib
12
Doxorubicin
12
Methotrexate
11
Fluorouracil
11
Vinblastine
10
Filgrastim
7
BCG Vaccine
7
Sorafenib
6
Ipilimumab
6
Immunoglobulin G
6
Disulfides
6
Biopsy
6
enfortumab vedotin
5
cabozantinib
5
Trastuzumab
5
Date Range
30 days
90 days
1 year
All
Options
Has results
Has announcements
Clinical Trials
1 trials
Recent
Start date
Enrollment
Phase 2
×
Urinary Bladder Neoplasms
×
linrodostat
×
Clear all
NCT03519256
2023-06-01
CheckMate 9UT
Bristol-Myers Squibb
Phase 2
Terminated
142 enrolled
20 charts